Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Amylyx Pharmaceuticals (AMLX) Net Margin: 2021-2024

Historic Net Margin for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to -141.71%.

  • Amylyx Pharmaceuticals' Net Margin fell 14527.00% to -141.71% in Q4 2024 from the same period last year, while for Dec 2024 it was -259.10%, marking a year-over-year decrease of 27047.00%. This contributed to the annual value of -263.74% for FY2024, which is 27511.00% down from last year.
  • According to the latest figures from Q4 2024, Amylyx Pharmaceuticals' Net Margin is -141.71%, which was up 99.19% from -17,476.92% recorded in Q3 2024.
  • Amylyx Pharmaceuticals' 5-year Net Margin high stood at 20.36% for Q2 2023, and its period low was -17,476.92% during Q3 2024.
  • Moreover, its 3-year median value for Net Margin was -137.86% (2024), whereas its average is -3,480.71%.
  • Its Net Margin has fluctuated over the past 5 years, first spiked by 984,610bps in 2023, then crashed by 1,749,560bps in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Net Margin (Quarterly) stood at -8,120.00% in 2021, then plummeted by 170,742bps to -164.94% in 2022, then soared by 16,850bps to 3.56% in 2023, then tumbled by 14,527bps to -141.71% in 2024.
  • Its last three reported values are -141.71% in Q4 2024, -17,476.92% for Q3 2024, and -7,106.55% during Q2 2024.